ARCH eyes $3B raise Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 1 September, 2026

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

presented by How the Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit is de-risk­ing Sau­di Ara­bi­a's cell and gene ther­a­py am­bi­tions

news Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused ARCH Venture Partners targets $3 billion raise for latest fund Take the Q3 Biopharma Sentiment Survey (BPSI)

Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable Sep 10 11:00 am ET Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence sponsored by Cellares Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

ENDPOINTS PHARMA Trump announces nine new drug pricing deals, this time with midsize biotechs Arrowhead claims safety edge over Ionis as triglyceride battle draws closer FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

in case you missed it 1. Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026 2. AstraZeneca's relaxin pill shows promise in mid-stage heart failure trial 3. Novartis pushes ahead with its IL-6 inhibitor despite Novo's failure 4. Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drug 5. She shut down Novo's cell therapies: Now she will lead a new Danish stem cell initiative MEDWATCH 6. Pharma stocks soar as investors seek AI alternatives